News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Cenexi reports an EBITDA breakeven for the quarter
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
cSCC is one of the most common cancers in the U.S. and globally
7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors
Subscribe To Our Newsletter & Stay Updated
